<?xml version="1.0" encoding="utf-8"?>
<Articles JournalTitle="Iranian Journal of Public Health">
    <Article>
        <Journal>
            <PublisherName>Shiraz University of Medical Sciences</PublisherName>
            <JournalTitle>Int Cardio Res J</JournalTitle>
            <Issn>2251-9149</Issn>
            <Volume>14</Volume>
            <Issue>3</Issue>
            <PubDate PubStatus="epublish">
                <Year>2020</Year>
                <Month>Sep</Month>
                <Day>01</Day>
            </PubDate>
            <journal_id_doi/>
        </Journal>
        <title locale="en_US">Covid- 19 and Myocardium</title>
        <AuthorList>
            <Author>
                <FirstName>Iman</FirstName>
                <LastName>Razeghian-Jahromi</LastName>
                <affiliation locale="en_US">Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran</affiliation>
            </Author>
            <Author>
                <FirstName>Zahra</FirstName>
                <LastName>Elyaspour</LastName>
                <affiliation locale="en_US">Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran</affiliation>
            </Author>
            <Author>
                <FirstName>Zahra</FirstName>
                <LastName>Daneshvar</LastName>
                <affiliation locale="en_US">Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran</affiliation>
            </Author>
            <Author>
                <FirstName>Mohammad Javad</FirstName>
                <LastName>Zibaeenezhad</LastName>
                <affiliation locale="en_US">Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran, Cardiovascular Research Center, Mohammad Rasoul-allah Research Tower, Mollasadra Street, Shiraz, Iran, Tel: +98-71-36122238, Email: zibaeem2@gmail.com.</affiliation>
            </Author>
        </AuthorList>
        <ArticleType>Review Article</ArticleType>
        <History>
            <PubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>Aug</Month>
                <Day>01</Day>
            </PubDate>
            <PubDate PubStatus="received">
                <Year>2020</Year>
                <Month>Sep</Month>
                <Day>15</Day>
            </PubDate>
            <PubDate PubStatus="epublish">
                <Year>2020</Year>
                <Month>Sep</Month>
                <Day>01</Day>
            </PubDate>
            <PubDate PubStatus="ppublish">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>30</Day>
            </PubDate>
        </History>
        <abstract locale="en_US">: 
        <strong>Context:</strong>The COVID-19 pandemic has involved several millions of people around the
        <br/>
 world and has dragged thousands of individuals to death. Unfortunately, it seems to be
        <br/>
 unstoppable for the near future. This review aimed to have a comprehensive appraisal
        <br/>
 on the latest studies conducted on different aspects of myocardial injury related to
        <br/>
 COVID-19.
        <br/>
        <strong>Evidence Acquisition:</strong>The researchers searched for accredited international
        <br/>
 investigations, whether original, review, letters, or commentaries or any other published
        <br/>
 data, in Pubmed/Medline, Google Scholar, Web of Science, Wiley Online Library, and
        <br/>
 Research Gate databases.
        <br/>
        <strong>Results:</strong>Although the dominant manifestation of the disease was related to the
        <br/>
 respiratory system, a growing body of evidence has suggested that the cardiovascular
        <br/>
 system was also a target for SARS-CoV-2. In this regard, myocardium suffered injury
        <br/>
 by possible direct and indirect mechanisms. Two patterns of myocardial injury were
        <br/>
 seen particularly in critical cases of COVID-19; presentation with acute myocardial
        <br/>
 injury and development of myocardial injury with escalation of the viral illness.
        <br/>
 In the case of myocardial damage, a cascade of life-threatening adverse events will
        <br/>
 deteriorate the functions of the cardiovascular system as well as other vital organs.
        <br/>
 Cardiac biomarkers are helpful for early diagnosis of myocardial injury. Hypertension,
        <br/>
 previous cardiovascular diseases, and diabetes have been considered to be the foremost
        <br/>
 clinical risk factors in the setting of COVID-19. The jeopardy of arrhythmia, thrombotic
        <br/>
 complications, acute myocardial infarction, and myocarditis are also anticipated in
        <br/>
 patients with COVID-19. Thrombolytics have been found to contribute substantially to
        <br/>
 life-saving treatment regimen.
        <br/>
        <strong>Conclusions:</strong>Cardiovascular damage in terms of myocardial injury has been assigned a
        <br/>
 considerable share in patients with COVID-19, which is of paramount importance due
        <br/>
 to the elevation of the fatality rate. While there is no exclusive medication for this viral
        <br/>
 uninvited guest, much attention should be paid to maintenance of cardiovascular health,
        <br/>
 which plays a critical role in the battlefield with COVID-19.</abstract>
        <web_url>https://sites.kowsarpub.com/ircrj/articles/107069.html</web_url>
        <pdf_url>No Link</pdf_url>
        <kwd-group>
            <kwd>Acute Heart Failure</kwd>
            <kwd>Myocardium</kwd>
            <kwd>COVID-19</kwd>
        </kwd-group>
    </Article>
</Articles>
